HDL drug carriers for targeted therapy

Area of Science:

• Biochemistry
• Cardiovascular Medicine
• Drug Delivery

Background:

• Plasma high-density lipoprotein cholesterol (HDL-C) concentrations are inversely correlated with cardiovascular risk.
• HDL possesses diverse anti-atherosclerosis functions beyond lipid transport, involving proteins, signaling lipids, and microRNAs.
• HDL's therapeutic potential is being explored for targeted drug delivery.

Purpose of the Study:

• To review four mechanisms that can enhance high-density lipoprotein (HDL) function and targeted therapy in vivo.
• To explore the potential of exploiting these mechanisms for improved clinical applications of HDL.

Main Methods:

• Review of literature focusing on four key mechanisms influencing HDL function and drug delivery.
• Discussion of HDL interactions involving caveolae, scavenger receptor class B type I (SR-BI), lecithin-cholesterol acyltransferase (LCAT), and microRNAs (miRNAs).

Main Results:

• Caveolae-mediated recruitment facilitates HDL signal receptor binding.
• SR-BI mediates HDL anchoring and fluidity for signal-lipid interactions.
• LCAT concentrates signaling lipids on the HDL surface.
• HDL particles can deliver specific microRNAs (miRNAs) to target cells.

Conclusions:

• Understanding and exploiting these four mechanisms can enhance HDL's capacity for targeted drug delivery.
• Targeted HDL therapies hold promise for increasing HDL's clinical value in cardiovascular disease management.